4CALDWELL S H, ARGO C K. Divergent effects of peroxisome proliferators-activated receptor-γ ligands in human and mouse nonalcoholic steatohepatitis [ J ]. Hepatology,2007,46 (2) :285-287.
5FRIEDMAN S L, ROCKEY D C, BISSELL D M. Hepati fibrosis 2006: Report of the third AASLD single tropic research conference [ J ]. Hepotlolgy, 2007,45 ( 1 ) :242-249.
6GRESSNER A M, WEISKIRCHEN R. Modem pathogenetic concepts of liver fibrosis suggest stellate cell and TGFβ1 as major player and therapeutic targets[J]. J Cell Mol Med,2006,10( 1 ) :76-99.
7FRIEDMAN S L, BANSAL M B. Reversal of hepatic fibrosis-fact or fantasy[ J]. Hepatslogy,2006,43 ( Suppl 2 ) :82-88.
8ALBANIS E, FRIEDMASN S L. Antifibrotic agents of liver disease [J]. Am J Transpl,2006,6(1 ) :12-19.
9MUHANNA N, AZZEH M, DORON S, et al. Immune modulator anti-fibrottic activity of SIRNAS in liver diseases [ J ]. Hepatology, 2006,44(4,suppl 1 ) :263.
10MCAVOY E F,KUBES P. Holey entothelium: Gate ways for nave T cell activatin[ J]. Hepatology,2006,44(5) :1083-1085.
